11.20.25 -- Is Passion A Criteria For Your CDMO Selection?

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Explore challenges associated with charged variants, including mAbs and fusion proteins.

Policy, trade, and security pressures are fundamentally reshaping global biologics manufacturing. Uncover practical steps sponsors can take to de-risk their supply chains proactively.

As interest grows in chemoenzymatic approaches to drug development, we wanted to know more about Sethera Therapeutics’ approach. Here’s what we were told.

To support complex modern therapies, bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms.

See how our expertise in formulation and process development can ensure a seamless scale-up from laboratory to full-scale production of lyophilized injectable products.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

Learn how a Stage-Gate approach to technology transfer and biomanufacturing can help to mitigate risk while shortening cycle times throughout the project lifecycle.

Evaluating quality attributes of therapeutic proteins requires a strategic, regulation-compliant selection of analytical techniques that consider molecular characteristics and phase to ensure characterization.

Stable bulk cultures, made highly uniform using transposase-mediated technologies, may be the key to expediting clone selection for many biopharmaceutical applications.

What is actually behind the procurement of a pharmaceutical labeling machine and how does the process work? You can find out here what the path to your pharmaceutical labeling machine looks like.

Many CDMOs cannot handle complex recombinant proteins, which often require a CLD process fully integrated with other CDMO components, including analytics and formulation development.

Ensuring container closure integrity in an increasingly complex pharmaceutical industry requires a holistic approach that incorporates quality control into all phases of product design and development.

GMP project delivery is a demanding endeavor. Find out why our skilled and well-managed teams, who use proven GMP information management software, are the right choice for your project.

In an increasingly competitive environment, working with the right CDMO is vital for successful drug lifecycle management. We now serve more than half of the world’s leading biopharma companies.

Recognized by the Arthritis Foundation®, the BD Physioject™ 1 mL Disposable Autoinjector is an easy-to-use autoinjector designed to deliver fixed dose injections subcutaneously.

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

Ensure the highest quality and sterility for your injectable manufacturing with proven aseptic expertise. Expect customer-first service, regulatory excellence, and a commitment to long-term success.

Watch how Lonza Biologics’ end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities.